HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal Of Clinical Pathology 2016, 146: 647-669. PMID: 28077399, PMCID: PMC6272805, DOI: 10.1093/ajcp/aqw206.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical decisionAmerican SocietyAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingClinical OncologyTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyClinical pathologyAmerican Pathologists